JP2006505499A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006505499A5 JP2006505499A5 JP2003581766A JP2003581766A JP2006505499A5 JP 2006505499 A5 JP2006505499 A5 JP 2006505499A5 JP 2003581766 A JP2003581766 A JP 2003581766A JP 2003581766 A JP2003581766 A JP 2003581766A JP 2006505499 A5 JP2006505499 A5 JP 2006505499A5
- Authority
- JP
- Japan
- Prior art keywords
- carnitine
- salt
- acid
- composition
- propionyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 12
- 239000002253 acid Substances 0.000 claims 10
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims 8
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims 8
- UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 claims 5
- 235000016709 nutrition Nutrition 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 4
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 206010067162 Asthenospermia Diseases 0.000 claims 2
- 208000007799 Asthenozoospermia Diseases 0.000 claims 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 229940009098 aspartate Drugs 0.000 claims 2
- 206010003549 asthenia Diseases 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 2
- 230000036244 malformation Effects 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 229940095064 tartrate Drugs 0.000 claims 2
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 claims 1
- XOAAWQZATWQOTB-UHFFFAOYSA-M 2-aminoethanesulfonate Chemical compound NCCS([O-])(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-M 0.000 claims 1
- QWJSAWXRUVVRLH-LREBCSMRSA-M 2-hydroxyethyl(trimethyl)azanium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound C[N+](C)(C)CCO.OC(=O)[C@H](O)[C@@H](O)C([O-])=O QWJSAWXRUVVRLH-LREBCSMRSA-M 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 claims 1
- 229960005336 magnesium citrate Drugs 0.000 claims 1
- 235000002538 magnesium citrate Nutrition 0.000 claims 1
- 239000004337 magnesium citrate Substances 0.000 claims 1
- 229940095060 magnesium tartrate Drugs 0.000 claims 1
- MUZDLCBWNVUYIR-ZVGUSBNCSA-L magnesium;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Mg+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O MUZDLCBWNVUYIR-ZVGUSBNCSA-L 0.000 claims 1
- QUIOHQITLKCGNW-TYYBGVCCSA-L magnesium;(e)-but-2-enedioate Chemical compound [Mg+2].[O-]C(=O)\C=C\C([O-])=O QUIOHQITLKCGNW-TYYBGVCCSA-L 0.000 claims 1
- YZURQOBSFRVSEB-UHFFFAOYSA-L magnesium;2-aminoethanesulfonate Chemical compound [Mg+2].NCCS([O-])(=O)=O.NCCS([O-])(=O)=O YZURQOBSFRVSEB-UHFFFAOYSA-L 0.000 claims 1
- -1 mucate Chemical compound 0.000 claims 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2002RM000194A ITRM20020194A1 (it) | 2002-04-09 | 2002-04-09 | Composizione utile per aumentare la concentrazione e la motilita' degli spermatozoi e migliorarne la morfologia nell'uomo. |
| PCT/IT2003/000214 WO2003084526A1 (en) | 2002-04-09 | 2003-04-08 | Combined use of l-carnitine, acetyl l-carnitine and propionyl l-carnitine for the treatment of oligoasthenoteratospermia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006505499A JP2006505499A (ja) | 2006-02-16 |
| JP2006505499A5 true JP2006505499A5 (enExample) | 2006-07-06 |
| JP4663987B2 JP4663987B2 (ja) | 2011-04-06 |
Family
ID=11456235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003581766A Expired - Lifetime JP4663987B2 (ja) | 2002-04-09 | 2003-04-08 | 精子減少・無力・奇形症の治療のためのｌ−カルニチン、アセチルｌ−カルニチンおよびプロピオニルｌ−カルニチンの併用 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20050107470A1 (enExample) |
| EP (1) | EP1492521B1 (enExample) |
| JP (1) | JP4663987B2 (enExample) |
| KR (1) | KR20040098005A (enExample) |
| CN (1) | CN1330301C (enExample) |
| AT (1) | ATE476974T1 (enExample) |
| AU (1) | AU2003224443B2 (enExample) |
| BR (1) | BR0309055A (enExample) |
| CA (1) | CA2478674C (enExample) |
| CY (1) | CY1111273T1 (enExample) |
| DE (1) | DE60333742D1 (enExample) |
| DK (1) | DK1492521T3 (enExample) |
| ES (1) | ES2350338T3 (enExample) |
| IT (1) | ITRM20020194A1 (enExample) |
| MX (1) | MXPA04009763A (enExample) |
| PL (1) | PL214859B1 (enExample) |
| PT (1) | PT1492521E (enExample) |
| SI (1) | SI1492521T1 (enExample) |
| WO (1) | WO2003084526A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776913B2 (en) | 2002-12-13 | 2010-08-17 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Carnitines for treating or preventing disorders caused by andropause |
| EP2429299B1 (en) | 2009-05-01 | 2016-06-01 | Celloxess Llc | Treating male infertility secondary to sperm oxidative stress |
| US20110015154A1 (en) * | 2009-07-20 | 2011-01-20 | Kellermann Gottfried H | Supporting acetylcholine function |
| US20110098265A1 (en) * | 2009-10-28 | 2011-04-28 | Neuroscience, Inc. | Methods for reducing cravings and impulses associated with addictive and compulsive behaviors |
| CN108041588A (zh) * | 2017-12-08 | 2018-05-18 | 冯纪敏 | 一种含有海藻糖的组合物及其应用 |
| CN109999042B (zh) * | 2019-05-16 | 2021-05-18 | 北京华睿鼎信科技有限公司 | 包含脱氢表雄酮或其硫酸酯、左卡尼汀、乙酰左卡尼汀或它们的可药用盐的组合物及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1249462B (it) * | 1991-10-21 | 1995-02-23 | Sigma Tau Ind Farmaceuti | Impiego di l-carnitina e acil l-carnitine nel trattamento delle oligoastenospermie idiopatiche. |
| IT1291127B1 (it) * | 1997-04-01 | 1998-12-29 | Sigma Tau Ind Farmaceuti | Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica |
| IT1295408B1 (it) * | 1997-10-03 | 1999-05-12 | Sigma Tau Ind Farmaceuti | Associazione di l-carnitina e alcanoil l-carnitine per il trattamento dell'alcoolismo |
| GB9721746D0 (en) | 1997-10-15 | 1997-12-10 | Panos Therapeutics Limited | Compositions |
| US6090848A (en) * | 1997-12-01 | 2000-07-18 | Sigma-Tau Healthscience S.P.A. | Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans |
| ITRM20010029A1 (it) * | 2001-01-23 | 2002-07-23 | Aldo Fassi | Sali metallici di carnitine utili come integratori dietetici/nutrizionali o come farmaci, composizioni che li contengono e procedimenti per |
| ITRM20020055A1 (it) | 2002-02-04 | 2003-08-04 | Aldo Fassi | Sali metallici di carnitine, integratori dietetici/nutritivi che li contengono e kit dietetici per contrastare disturbi sessuali in soggetti |
-
2002
- 2002-04-09 IT IT2002RM000194A patent/ITRM20020194A1/it unknown
-
2003
- 2003-04-08 ES ES03720869T patent/ES2350338T3/es not_active Expired - Lifetime
- 2003-04-08 AU AU2003224443A patent/AU2003224443B2/en not_active Expired
- 2003-04-08 MX MXPA04009763A patent/MXPA04009763A/es active IP Right Grant
- 2003-04-08 WO PCT/IT2003/000214 patent/WO2003084526A1/en not_active Ceased
- 2003-04-08 AT AT03720869T patent/ATE476974T1/de active
- 2003-04-08 CN CNB038050935A patent/CN1330301C/zh not_active Expired - Lifetime
- 2003-04-08 KR KR10-2004-7013385A patent/KR20040098005A/ko not_active Ceased
- 2003-04-08 PT PT03720869T patent/PT1492521E/pt unknown
- 2003-04-08 US US10/510,450 patent/US20050107470A1/en not_active Abandoned
- 2003-04-08 JP JP2003581766A patent/JP4663987B2/ja not_active Expired - Lifetime
- 2003-04-08 EP EP03720869A patent/EP1492521B1/en not_active Expired - Lifetime
- 2003-04-08 SI SI200331892T patent/SI1492521T1/sl unknown
- 2003-04-08 PL PL372924A patent/PL214859B1/pl unknown
- 2003-04-08 CA CA2478674A patent/CA2478674C/en not_active Expired - Lifetime
- 2003-04-08 DE DE60333742T patent/DE60333742D1/de not_active Expired - Lifetime
- 2003-04-08 BR BR0309055-8A patent/BR0309055A/pt not_active Application Discontinuation
- 2003-04-08 DK DK03720869.1T patent/DK1492521T3/da active
-
2008
- 2008-09-09 US US12/230,992 patent/US8415392B2/en not_active Expired - Fee Related
-
2010
- 2010-11-03 CY CY20101100989T patent/CY1111273T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20010005865A (ko) | 격렬한 운동에 대한 골격근 적응을 촉진하고 허약 체질자의 피로 회복에 유용한 영양 보조제 | |
| AU627041B2 (en) | Improved nutritional formulation for the treatment of renal disease | |
| PT914315E (pt) | Sais nao higroscopicos estaveis de l(-)carnitina e alcanoil l(-)carnitinas processo para a sua preparacao e composicoes solidas administraveis oralmente contendo tais sais | |
| JP2006505499A5 (enExample) | ||
| JP2001518484A5 (enExample) | ||
| JP2007501817A5 (enExample) | ||
| JP2009512430A5 (enExample) | ||
| CA2505937A1 (en) | Acetyl-l-carnitine for the prevention and/or treatment of peripheral neuropaties induced by anticancer agents | |
| JP2005523269A5 (enExample) | ||
| JP2006508958A5 (enExample) | ||
| CA2478674A1 (en) | Combined use of l-carnitine, acetyl l-carnitine and propionyl l-carnitine for the treatment of oligoasthenoteratospermia | |
| HRP20120138T1 (hr) | Energetski dodatak prehrani za skeletne mišiće i za zaštitu kardiovaskularnog sustava | |
| JP2006511531A5 (enExample) | ||
| AU2020222897B2 (en) | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use | |
| JP2005511655A5 (enExample) | ||
| CA2465471A1 (en) | Use of alkanoyl l-carnitine for the treatment of erectile dysfunction | |
| CA2507429A1 (en) | Use of carnitines for the prevention and/or treatment of disorders caused by the andropause | |
| JP2023174946A (ja) | Ｓ－エナンチオマー富化組成物およびキット | |
| JP2004532866A5 (enExample) | ||
| JP2006523685A5 (enExample) | ||
| CA2508636A1 (en) | Use of l-carnitine for the treatment of cardiovascular diseases | |
| JP2008534433A5 (enExample) | ||
| JP2008531466A5 (enExample) | ||
| CA2585654C (en) | Use of acetyl l-carnitine in combination with propionyl l-carnitine and sildenafil for the treatment of erectile dysfunction | |
| RU2003116133A (ru) | Твердые композиции для перорального применения, содержащие негигроскопичные соли l-карнитина и алканоил l-карнитинов с хлористым таурином и хлористым глицином |